NewsInotec AMD Limited appoints new CEO

Inotec AMD Limited appoints new CEO


Inotec AMD Limited appoints new CEOCambridge based Inotec AMD Limited is pleased to announce the appointment of Craig Kennedy as its new Chief Executive Officer on 3 March 2018.

Craig Kennedy brings on board a proven track record of building business in the wound care space. Most recently, he was CEO of MolecuLight, a Toronto Canada based wound care start up that developed and launched a imaging device capable of detecting bacteria in wounds.  Prior to MolecuLight, Craig was VP of Business Development and Strategy for Systagenix and was a key member in the divestiture of that business to Acelity.  Craig has over 25 years of progressive experience in the medical device and pharmaceutical industry. 

Dr Adrian Parton MBE, Chairman of Inotec AMD said “The Board of Directors are pleased to announce the appointment of Craig Kennedy who will be starting his new role as CEO of the company in March and we believe that his extensive global experience of the wound care market will help the Company drive the growth of Inotec AMD’s novel oxygen therapy products on a global basis”.  


Mr Kennedy commented that "I am excited to lead the Inotec AMD team at this exciting time.  NATROX® is an excellent product with great potential to positively impact the lives of millions of people living with debilitating chronic wounds.  The industry is ripe for the introduction of clinically effective active therapy to improve the lives of millions living with these wounds."